A rationally designed A34R mutant oncolytic poxvirus: Improved efficacy in peritoneal carcinomatosis

Molecular Therapy

Volumn 21, Issue 5, 2013, Pages 1024-1033

  Thirunavukarasu, Pragatheeshwar ^a,b   Sathaiah, Magesh ^a,b   Gorry, Michael C ^a,b   O'Malley, Mark E ^a,b   Ravindranathan, Roshni ^a,b   Austin, Frances ^a,b   Thorne, Steven H ^a,b   Guo, Zong Sheng ^a,b   Bartlett, David L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC POXVIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

A34R GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE MUTATION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PERITONEAL CARCINOMATOSIS; PERITONEUM TUMOR; TUMOR ESCAPE; VIRUS GENE; VIRUS MUTANT; VIRUS REPLICATION;

POXVIRIDAE; VACCINIA VIRUS;

EID: 84877043006     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.27     Document Type: Conference Paper

References (49)

1. Bourke, MG, Salwa, S, Harrington, KJ, Kucharczyk, MJ, Forde, PF, de Kruijf, M et al. (2011). The emerging role of viruses in the treatment of solid tumours. Cancer Treat Rev 37: 618-632.
2. Stanford, MM, Bell, JC and Vähä-Koskela, MJ (2010). Novel oncolytic viruses: riding high on the next wave Cytokine Growth Factor Rev 21: 177-183.
3. Guo, ZS, Thorne, SH and Bartlett, DL (2008). Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 1785: 217-231.
4. Doceul, V, Hollinshead, M, van der Linden, L and Smith, GL (2010). Repulsion of superinfecting virions: a mechanism for rapid virus spread. Science 327: 873-876.
5. Roberts, KL and Smith, GL (2008). Vaccinia virus morphogenesis and dissemination. Trends Microbiol 16: 472-479.
6. Kirn, DH and Thorne, SH (2009). Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 9: 64-71.
7. McCart, JA, Ward, JM, Lee, J, Hu, Y, Alexander, HR, Libutti, SK et al. (2001). Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61: 8751-8757.
8. Guo, ZS, Naik, A, O'Malley, ME, Popovic, P, Demarco, R, Hu, Y et al. (2005). The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 65: 9991-9998.
9. Zhang, Q, Yu, YA, Wang, E, Chen, N, Danner, RL, Munson, PJ et al. (2007). Eradication of solid human breast tumors in nude mice with an intravenously injected lightemitting oncolytic vaccinia virus. Cancer Res 67: 10038-10046.
10. Kirn, DH, Wang, Y, Liang, W, Contag, CH and Thorne, SH (2008). Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res 68: 2071-2075.
11. Sathaiah, M, Thirunavukkarasu, P, O'Malley, ME, Kavanagh, MA, Ravindranathan, R, Austin, F et al. (2012). Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer. Cancer Gene Ther 19: 192-201.
12. Breitbach, CJ, Burke, J, Jonker, D, Stephenson, J, Haas, AR, Chow, LQ et al. (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477: 99-102.
13. Parato, KA, Breitbach, CJ, Le Boeuf, F, Wang, J, Storbeck, C, Ilkow, C et al. (2012). The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 20: 749-758.
14. Puhlmann, M, Brown, CK, Gnant, M, Huang, J, Libutti, SK, Alexander, HR et al. (2000). Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 7: 66-73.
15. Buller, RM, Chakrabarti, S, Moss, B and Fredrickson, T (1988). Cell proliferative response to vaccinia virus is mediated by VGF. Virology 164: 182-192.
16. Blasco, R, Sisler, JR and Moss, B (1993). Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene. J Virol 67: 3319-3325.
17. Smith, GL, Murphy, BJ and Law, M (2003). Vaccinia virus motility. Annu Rev Microbiol 57: 323-342.
18. Smith, GL, Vanderplasschen, A and Law, M (2002). The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83(Pt 12): 2915-2931.
19. McIntosh, AA and Smith, GL (1996). Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. J Virol 70: 272-281.
20. Locker, JK, Kuehn, A, Schleich, S, Rutter, G, Hohenberg, H, Wepf, R et al. (2000). Entry of the two infectious forms of vaccinia virus at the plasma membrane is signalingdependent for the IMV but not the EEV. Mol Biol Cell 11: 2497-2511.
21. Smith, GL and Vanderplasschen, A (1998). Extracellular enveloped vaccinia virus. Entry, egress, and evasion. Adv Exp Med Biol 440: 395-414.
22. Vanderplasschen, A, Mathew, E, Hollinshead, M, Sim, RB and Smith, GL (1998). Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci USA 95: 7544-7549.
23. Vanderplasschen, A, Hollinshead, M and Smith, GL (1998). Intracellular and extracellular vaccinia virions enter cells by different mechanisms. J Gen Virol 79 (Pt 4): 877-887.
24. Vanderplasschen, A and Smith, GL (1997). A novel virus binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors. J Virol 71: 4032-4041.
25. Payne, LG (1980). Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J Gen Virol 50: 89-100.
26. Krauss, O, Hollinshead, R, Hollinshead, M and Smith, GL (2002). An investigation of incorporation of cellular antigens into vaccinia virus particles. J Gen Virol 83(Pt 10): 2347-2359.
27. Ichihashi, Y (1996). Extracellular enveloped vaccinia virus escapes neutralization. Virology 217: 478-485.
28. Vanderplasschen, A, Hollinshead, M and Smith, GL (1997). Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J Gen Virol 78 (Pt 8): 2041-2048.
29. Coukos, G, Makrigiannakis, A, Kang, EH, Caparelli, D, Benjamin, I, Kaiser, LR et al. (1999). Use of carrier cells to deliver a replication- selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 5: 1523-1537.
30. Wildner, O and Morris, JC (2000). Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses. J Gene Med 2: 353-360.
31. Bennett, JJ, Delman, KA, Burt, BM, Mariotti, A, Malhotra, S, Zager, J et al. (2002). Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther 9: 935-945.
32. Chalikonda, S, Kivlen, MH, O'Malley, ME, Eric Dong, XD, McCart, JA, Gorry, MC et al. (2008). Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther 15: 115-125.
33. Guo, ZS, Parimi, V, O'Malley, ME, Thirunavukarasu, P, Sathaiah, M, Austin, F et al. (2010). The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host. Gene Ther 17: 1465-1475.
34. Sadeghi, B, Arvieux, C, Glehen, O, Beaujard, AC, Rivoire, M, Baulieux, J et al. (2000). Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88: 358-363.
35. Koppe, MJ, Boerman, OC, Oyen, WJ and Bleichrodt, RP (2006). Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 243: 212-222.
36. Cao, CQ, Yan, TD, Liauw, W and Morris, DL (2009). Comparison of optimally resected hepatectomy and peritonectomy patients with colorectal cancer metastasis. J Surg Oncol 100: 529-533.
37. Davies, JM and O'Neil, B (2009). Peritoneal carcinomatosis of gastrointestinal origin: natural history and treatment options. Expert Opin Investig Drugs 18: 913-919.
38. Piso, P, Glockzin, G, von Breitenbuch, P, Popp, FC, Dahlke, MH, Schlitt, HJ et al. (2009). Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. J Surg Oncol 100: 317-320.
39. Jacquet, P and Sugarbaker, PH (1996). Peritoneal-plasma barrier. Cancer Treat Res 82: 53-63.
40. Raykov, Z and Rommelaere, J (2008). Potential of tumour cells for delivering oncolytic viruses. Gene Ther 15: 704-710.
41. Willmon, C, Harrington, K, Kottke, T, Prestwich, R, Melcher, A and Vile, R (2009). Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther 17: 1667-1676.
42. Kusamura, S, Baratti, D, Zaffaroni, N, Villa, R, Laterza, B, Balestra, MR et al. (2010). Pathophysiology and biology of peritoneal carcinomatosis. World J Gastrointest Oncol 2: 12-18.
43. Fujiwara, S, Nawa, A, Luo, C, Kamakura, M, Goshima, F, Kondo, C et al. (2011). Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer. Cancer Gene Ther 18: 77-86.
44. Lindenmann, J and Klein, PA (1967). Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med 126: 93-108.
45. Hu, W, Davis, JJ, Zhu, H, Dong, F, Guo, W, Ang, J et al. (2007). Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy. Cancer Biol Ther 6: 1773-1779.
46. Bridle, BW, Stephenson, KB, Boudreau, JE, Koshy, S, Kazdhan, N, Pullenayegum, E et al. (2010). Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 18: 1430-1439.
47. Prestwich, RJ, Harrington, KJ, Pandha, HS, Vile, RG, Melcher, AA and Errington, F (2008). Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther 8: 1581-1588.
48. John, LB, Howland, LJ, Flynn, JK, West, AC, Devaud, C, Duong, CP et al. (2012). Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res 72: 1651-1660.
49. Li, J, O'Malley, M, Urban, J, Sampath, P, Guo, ZS, Kalinski, P et al. (2011). Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther 19: 650-657.